Peroxisome Restoration Therapy represents a novel therapeutic approach targeting peroxisomal dysfunction, a common yet underappreciated feature of neurodegenerative diseases. Peroxisomes are essential organelles involved in very-long-chain fatty acid (VLCFA) catabolism, plasmalogen synthesis, and reactive oxygen species (ROS) metabolism. Peroxisomal dysfunction leads to accumulation of VLCFAs, loss of plasmalogens (ether phospholipids critical for myelin and neuronal membrane integrity), and impaired lipid signaling—all contributing to neurodegeneration.
Primary Target: Peroxisomal biogenesis and function restoration
Key Molecular Targets:
Peroxisome Restoration Therapy employs a multi-pronged approach:
| Disease | Evidence for Peroxisomal Dysfunction |
|---|---|
| Alzheimer's Disease | Decreased peroxisome number in AD brain (Sandhir 2004); reduced plasmalogens in AD CSF and brain tissue (Moser 2007); PEX5 dysfunction linked to Aβ pathology |
| Parkinson's Disease | Reduced peroxisomes in PD substantia nigra (McCarron 2019); VLCFA accumulation in PD brain; PINK1-Parkin mitophagy intersects with peroxisome quality control |
| ALS | Peroxisomal loss in motor neurons (Kovacs 2004); elevated VLCFAs in ALS patients; ACOX1 mutations linked to childhood neurological disease |
| Aging | Declining peroxisome function is a hallmark of cellular aging; peroxisome-biogenesis defects cause Zellweger spectrum disorders with severe neurological phenotypes |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8/10 | Novel therapeutic category — peroxisome restoration is underexplored compared to mitochondrial targeting |
| Mechanistic Rationale | 9/10 | Strong mechanistic link: peroxisomal dysfunction documented in AD, PD, ALS; plasmalogen deficiency directly impacts neuronal membranes |
| Root-Cause Coverage | 8/10 | Addresses fundamental cellular organelle dysfunction, not just symptoms |
| Delivery Feasibility | 7/10 | BBB penetration achievable with some PPAR agonists; plasmalogen precursors can be orally administered |
| Safety Plausibility | 8/10 | PPAR agonists (fenofibrate, bezafibrate) have established safety profiles; plasmalogens are endogenous lipids |
| Combinability | 9/10 | Synergistic with mitochondrial therapies, autophagy enhancers, and lipid-targeting approaches |
| Biomarker Availability | 7/10 | VLCFA levels (C22:0, C24:0, C26:0), plasmalogen ratios in plasma/CSF can serve as biomarkers |
| De-risking Path | 7/10 | Can progress through standard Phase I-II design using established compounds |
| Multi-disease Potential | 9/10 | Applicable to AD, PD, ALS, FTD, aging-related neurodegeneration |
| Patient Impact | 8/10 | Addresses core lipid dysregulation affecting broad patient populations |
Total Score: 71/100
| Disease | Coverage Score | Rationale |
|---|---|---|
| Alzheimer's Disease | 9 | Strongest evidence: peroxisomal loss, plasmalogen deficiency in AD brain and CSF |
| Parkinson's Disease | 8 | VLCFA accumulation in PD brain; peroxisome deficiency in substantia nigra |
| ALS | 8 | Peroxisomal dysfunction in motor neurons; VLCFA elevation in patients |
| FTD | 6 | Less direct evidence, but peroxisomal dysfunction implicated in some genetic forms |
| PSP | 6 | Limited data, but 4R-tauopathies show lipid metabolism alterations |
| MSA | 6 | Oligodendrocyte peroxisomal function relevant to GCI pathology |
| Aging | 8 | Peroxisome decline is a key cellular aging hallmark |